about
Genome-wide association analyses identify 18 new loci associated with serum urate concentrationsGenetic variants in novel pathways influence blood pressure and cardiovascular disease riskAttenuation of renovascular damage in Zucker diabetic fatty rat by NWT-03, an egg protein hydrolysate with ACE- and DPP4-inhibitory ActivityThe Plk1 inhibitor BI 2536 temporarily arrests primary cardiac fibroblasts in mitosis and generates aneuploidy in vitroMortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial IThe EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatmentGenome-wide association study for circulating tissue plasminogen activator levels and functional follow-up implicates endothelial STXBP5 and STX2.Genome-wide association study for circulating levels of PAI-1 provides novel insights into its regulationUltrasound and microbubble-targeted delivery of therapeutic compounds: ICIN Report Project 49: Drug and gene delivery through ultrasound and microbubbles.Telomere length and outcomes in ischaemic heart failure: data from the COntrolled ROsuvastatin multiNAtional Trial in Heart Failure (CORONA).Determinants of temporal changes in galectin-3 level in the general population: Data of PREVEND.Reduction of exercise-induced myocardial ischemia during add-on treatment with the angiotensin-converting enzyme inhibitor enalapril in patients with normal left ventricular function and optimal beta blockade.A role for CETP TaqIB polymorphism in determining susceptibility to atrial fibrillation: a nested case control studyC-reactive protein and angiographic characteristics of stable and unstable coronary artery disease: data from the prospective PREVEND cohort.Telomere biology in healthy aging and disease.Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms.Monitoring initial response to Angiotensin-converting enzyme inhibitor-based regimens: an individual patient data meta-analysis from randomized, placebo-controlled trials.Cardiovascular risk associated with interactions among polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems52 Genetic Loci Influencing Myocardial Mass.Genetic determinants of P wave duration and PR segmentCommon variants in 22 loci are associated with QRS duration and cardiac ventricular conduction.Microbubbles and ultrasound: from diagnosis to therapy.A Simple and Computationally Efficient Approach to Multifactor Dimensionality Reduction Analysis of Gene-Gene Interactions for Quantitative Traits.A genome-wide association study of circulating galectin-3Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense?Trans-ancestry genome-wide association study identifies 12 genetic loci influencing blood pressure and implicates a role for DNA methylation.Pathophysiologic and therapeutic importance of tissue ACE: a consensus report.The Association of the Metabolic Syndrome with PAI-1 and t-PA LevelsAtrial remodeling is directly related to end-diastolic left ventricular pressure in a mouse model of ventricular pressure overload.Effects of quinapril, losartan and hydralazine on cardiac hypertrophy and beta-adrenergic neuroeffector mechanisms in transgenic (mREN2)27 rats.AKIP1 expression modulates mitochondrial function in rat neonatal cardiomyocytesCardiac function and architecture are maintained in a model of cardiorestricted overexpression of the prorenin-renin receptor.The impact of coronary artery disease risk loci on ischemic heart failure severity and prognosis: association analysis in the COntrolled ROsuvastatin multiNAtional trial in heart failure (CORONA).Epistatic effects of polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems on plasma t-PA and PAI-1 levels.Erythropoietin in cardiovascular diseases.Association between chromosome 9p21 variants and the ankle-brachial index identified by a meta-analysis of 21 genome-wide association studies.β-blocker Therapy is Not Associated with Reductions in Angina or Cardiovascular Events After Coronary Artery Bypass Graft Surgery: Insights from the IMAGINE Trial.Framingham score and microalbuminuria: combined future targets for primary prevention?Galectin-3, Renal Function, and Clinical Outcomes: Results from the LURIC and 4D StudiesClinical impact of vasomotor function assessment and the role of ACE-inhibitors and statins.
P50
Q24620065-E6682FC8-C938-446D-94B1-81E1948409EEQ24630394-B599E1AE-904C-49D4-AA88-0D7763DCA942Q27315825-8C0745D9-3AB9-4204-967D-B80926E0E070Q27319063-F0A20C6E-F66F-4F46-A82B-CFC3CB70605FQ28193469-8A3E55C0-C3BD-4892-9F05-24A1B043B203Q28195357-A8D54292-5894-463E-8B49-A749C25E9759Q28658007-750552FB-D535-4F2B-80F1-86DFD5164919Q30415902-324A7CFA-7641-47CE-9F93-CC3BD4C8B9C0Q30491066-CF2CC5E2-8216-4369-B666-ECFFCC8BB3BEQ30886908-F8D25E70-ECD3-485E-9229-A82FB8D8481EQ31120548-A9F06A51-CB52-4771-AC2E-500670ED5CC0Q32055028-40269674-F42A-4E99-94EA-559052B88374Q33240337-9984347E-B76B-4F92-B358-700FDE51CD71Q33266017-8E77CB57-F010-4859-BC0E-159769C01C96Q33572237-DFDE1DD3-D526-4D6C-8A0A-30EA6042E8E7Q33612543-B624CED2-0148-4FDD-9085-0E7E420A0A99Q33631038-2DD8075A-D10A-4C47-8BEB-BB707E16DBDCQ33697706-6EE40C4F-F57D-4F0C-8BF8-B2AEB2326320Q33817558-C8F4D109-1658-4BFB-9DBB-E1BC33F098A5Q34076355-43B1EA70-3035-497D-B244-16EC9CB8A482Q34149773-296CF8FF-464F-4426-8F1A-5AA0909F1C78Q34329287-2B2B2460-397D-43E0-97A0-DA1ED7553ADBQ34353866-E6B0E7AC-AE0B-4881-B081-87677260387BQ34443077-3A335730-BDB5-4A46-81D8-FCDA5AF74953Q34443692-7D2BD493-99E9-4B65-B02E-962E6C7E5D70Q34495057-3BAA415E-FFFE-4BF8-A375-3E9675AA2BEDQ34714408-4ACC5996-DA8D-4A9C-9A59-82A28B20D7EFQ34929646-E12EC26F-04B1-416D-8555-4C8CD055DD18Q34988512-98B187FC-E51B-41AC-B9C3-F727C6B891AEQ35027144-4571D985-1433-42B7-B8AE-92470611D2DFQ35044013-19568C66-8A3E-4265-A38F-C656540EE79CQ35108388-C39F455A-1B5D-4619-BF9B-5A1C96999919Q35531512-59A0E73D-BCCA-4212-8BE5-2DECC4EE8045Q35658814-CEC11EF4-BD3F-4A59-8DB0-8823E96D9B39Q35676092-F5E47D11-D9CA-46E4-8DB4-89E5FFF54BA6Q35828701-F3B7FBDD-F63D-4DD2-9408-8DCB3C75AC26Q35907989-E7B5ED75-084D-43BA-BDC7-C4B5C14C035AQ35918614-429D509E-0BF8-4222-A68A-1CA82CF8E7FEQ36003071-6D97A589-068E-44D5-8C33-0E28E0E40FDBQ36081210-73FF11C8-041E-4C2A-9BD1-D8EC52B828E2
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Wiek H van Gilst
@ast
Wiek H van Gilst
@en
Wiek H van Gilst
@es
Wiek H van Gilst
@nl
Wiek H van Gilst
@sl
type
label
Wiek H van Gilst
@ast
Wiek H van Gilst
@en
Wiek H van Gilst
@es
Wiek H van Gilst
@nl
Wiek H van Gilst
@sl
altLabel
Wiek van Gilst
@en
prefLabel
Wiek H van Gilst
@ast
Wiek H van Gilst
@en
Wiek H van Gilst
@es
Wiek H van Gilst
@nl
Wiek H van Gilst
@sl
P106
P1153
7103238396
P31
P3835
wiek-van-gilst
P496
0000-0003-2968-8585